Kansas City Gastroenterology and Hepatology

Kansas City, Missouri 64131

0 studies enrolling now · 17 studies all time

What they study most

Chronic Hepatitis C, Chronic Hepatitis C Virus, Crohn's Disease, Gastroesophageal Reflux Disease (GERD), HBV, Hepatitis B, Hepatitis C, Hepatitis C Virus, Hepatitis C, Chronic, Nonalcoholic Steatohepatitis, Primary Biliary Cirrhosis (PBC), Ulcerative Colitis

Studies at this site

• Study to Evaluate the Effects of Two Doses of Seladelpar (MBX-8025) in Subjects With Primary Biliary Cirrhosis (PBC) — Stopped early
• A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs) — Stopped early
• Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Participants With Chronic HCV Infection — Completed
• Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis — Stopped early
• Longitudinal Assessment of Cardiovascular and Renal Health in Patients With Hepatitis-C (CARE-Hep C) — Completed
• A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response — Completed
• Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies — Completed
• A Study of Abatacept in Patients With Active Ulcerative Colitis — Completed
• Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION) — Completed
• Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon — Completed
• Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection — Completed
• Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients — Completed
• A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection — Completed
• A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B — Completed
• A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C — Completed
• Efficacy and Tolerability Study of Natura-Alpha in the Treatment of Patients With Active Ulcerative Colitis — Status unconfirmed
• A Study of Abatacept in Patients With Active Crohn's Disease — Stopped early